Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody.Statement on a nonproprietary name adopted by the USAN Council: Vedotin It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.
MMAE is actually desmethyl-auristatin E; that is, the N-terminal amino group has only one methyl substituent instead of two as in auristatin E itself.
Mechanism of action Monomethyl auristatin E is an antimitotic agent which inhibits cell division by blocking the polymerisation of tubulin. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the antimitotic mechanism.Seattle Genetics: Brentuximab vedotin (SGN-35)
Monoclonal antibodies/ADCs MMAE has been tested with various monoclonal antibodies (usually forming an antibody-drug conjugate). targeting the protein CD30 which is found on malignant cells in anaplastic large cell lymphoma and Hodgkin's lymphoma: Brentuximab (cAC10), 3–5 units of MMAE per molecule targeting the glycoprotein GPNMB which is found in aggressive melanoma, glioma, breast cancer and other tumours: Glembatumumab (CR011, CDX-011), investigated for the treatment of breast cancer and melanomaMedical News Today: CuraGen Announces Expansion Of CR011-vcMMAE Phase II Trial In Advanced Breast CancerNCI Drug Dictionary: Glembatumumab vedotin targeting CD37: AGS67E, to treat lymphoid malignancyA study of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies targeting tissue factor in recurrent or persistent cervical cancers that progress on or after first line chemotherapy regimens: tisotumab vedotin
Examples: Sofituzumab vedotin Polatuzumab vedotin (RG7596) Enfortumab vedotin Pinatuzumab vedotin Lifastuzumab vedotin Brentuximab vedotin Glembatumumab vedotin Tisotumab vedotin Indusatumab vedotin (MLN-0264) in phase II trialsIndusatumab vedotin (MLN-0264) Clinical Trials. March 2015
See also Seattle Genetics Monomethyl auristatin F
References